These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2661369)

  • 1. [Drug treatment of proliferative vitreoretinopathy].
    Wiedemann P
    Fortschr Ophthalmol; 1989; 86(2):115-20. PubMed ID: 2661369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proliferative vitreoretinopathy. Pathogenesis and possibilities for treatment with cytostatic drugs].
    Wiedemann P; Heimann K
    Klin Monbl Augenheilkd; 1986 Jun; 188(6):559-64. PubMed ID: 3761957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro.
    Cai J; Wei R; Ma X; Zhu H; Li Y
    Int Ophthalmol; 2001; 24(4):225-31. PubMed ID: 12678400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.
    Wiedemann P; Sorgente N; Bekhor C; Patterson R; Tran T; Ryan SJ
    Invest Ophthalmol Vis Sci; 1985 May; 26(5):719-25. PubMed ID: 3997421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proliferative vitreoretinopathy: prophylactic treatment].
    Chiquet C; Rouberol F
    J Fr Ophtalmol; 2014 Nov; 37(9):737-43. PubMed ID: 25012973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy.
    Esser P; Tervooren D; Heimann K; Kociok N; Bartz-Schmidt KU; Walter P; Weller M
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):164-70. PubMed ID: 9430558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proliferative vitreoretinopathy: pathophysiology and clinical diagnosis].
    Rouberol F; Chiquet C
    J Fr Ophtalmol; 2014 Sep; 37(7):557-65. PubMed ID: 24997864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular migration, proliferation, and contraction. An in vitro approach to a clinical problem--proliferative vitreoretinopathy.
    Verdoorn C; Renardel de Lavalette VW; Dalma-Weizhausz J; Orr GM; Sorgente N; Ryan SJ
    Arch Ophthalmol; 1986 Aug; 104(8):1216-9. PubMed ID: 2874784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.
    Chen EP; Steinhorst UH; Samsa GP; Saloupis PT; Hatchell DL
    Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2160-4. PubMed ID: 1607226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy].
    Bi HS; Cui Y; Zhang JH; Wang XR; Xie XF
    Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):37-41. PubMed ID: 16638279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxol for the treatment of proliferative vitreoretinopathy.
    van Bockxmeer FM; Martin CE; Thompson DE; Constable IJ
    Invest Ophthalmol Vis Sci; 1985 Aug; 26(8):1140-7. PubMed ID: 2862129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Proliferative vitreoretinopathy: new discoveries in pathophysiology and therapy].
    Wiedemann P; Weller M; Heimann K
    Klin Monbl Augenheilkd; 1990 Nov; 197(5):355-61. PubMed ID: 2290290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
    Hou H; Huffman K; Rios S; Freeman WR; Sailor MJ; Cheng L
    Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2755-63. PubMed ID: 25829415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
    Kuo HK; Wu PC; Yang PM; Chen YH; Wu YC; Hu DN
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):14-20. PubMed ID: 17341145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A survey of clinically used drugs in PVR: a review].
    Faude F; Heimann K; Wiedemann P
    Klin Monbl Augenheilkd; 1999 Jun; 214(6):362-6. PubMed ID: 10427537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.
    Joondeph BC; Peyman GA; Khoobehi B; Yue BY
    Ophthalmic Surg; 1988 Apr; 19(4):252-6. PubMed ID: 3362494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of drug treatments for proliferative vitreoretinopathy using vitreous microtensiometry.
    Moorhead LC; Sepahban S; Armeniades CD
    Ann Ophthalmol; 1991 Sep; 23(9):349-55. PubMed ID: 1741609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiproliferative effect of sustained drug delivery system of all-trans retinoic acid implant into rabbit's vitreous cavity for treatment of proliferative vitreoretinopathy].
    Yan XR; Dong XG; Chen N; Wang W
    Zhonghua Yan Ke Za Zhi; 2003 Oct; 39(10):621-5. PubMed ID: 14766078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Daunomycin and silicone oil in treatment of proliferative vitreoretinopathy].
    Wiedemann P; Leinung C; Hilgers RD; Heimann K
    Fortschr Ophthalmol; 1991; 88(6):613-5. PubMed ID: 1794777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experimental proliferative vitreoretinopathy in rabbits after intravitreous gas injection and creation of retinal hole: ophthalmic findings and localization of fibronectin].
    Iwasaki T
    Nippon Ganka Gakkai Zasshi; 1992 May; 96(5):613-9. PubMed ID: 1621606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.